2. Search Result
Search Result
Results for "

myelosuppression

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

5

Natural
Products

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W145521
    β-1,3-Glucan
    1 Publications Verification

    β Glucan

    		 Biochemical Assay Reagents IKK NO Synthase Bacterial Infection Inflammation/Immunology Cancer
    β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to Vibrio harveyi infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors .
    β-1,3-Glucan
  • HY-10966
    SB-590885
    Maximum Cited Publications
    8 Publications Verification

    		 Raf Apoptosis Neurological Disease Metabolic Disease Cancer
    SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
    SB-590885
  • HY-101467
    Trilaciclib
    1 Publications Verification

    G1T28

    		 CDK Cancer
    Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
    Trilaciclib
  • HY-19915
    Contezolid
    3 Publications Verification

    MRX-I

    		 Bacterial Antibiotic Monoamine Oxidase Infection Inflammation/Immunology
    Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI) .
    Contezolid
  • HY-124593
    PTC299
    5 Publications Verification

    Emvododstat

    		 VEGFR Dihydroorotate Dehydrogenase DNA/RNA Synthesis Cancer
    PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies .
    PTC299
  • HY-W097899
    Vanillylamine
    1 Publications Verification

    		 JNK Cancer
    Vanillylamine is an immediate precursor for capsaicinoids. Vanillylamine is a derivative of Vanillin (HY-N0098) is synthesized through a transaminase reaction in the phenylpropanoid pathway of capsaicinoid synthesis. Vanillylamine significantly alleviates myelosuppression caused by abdominal and pelvic tumor chemotherapy .
    Vanillylamine
  • HY-N7114A
    Chloramphenicol succinate sodium
    3 Publications Verification

    		 Bacterial P2Y Receptor Succinate Dehydrogenase Drug Intermediate Infection Inflammation/Immunology
    Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate sodium
  • HY-101467A
    Trilaciclib hydrochloride
    1 Publications Verification

    G1T28 hydrochloride

    		 CDK Cancer
    Trilaciclib (G1T28) hydrochloride is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
    Trilaciclib hydrochloride
  • HY-13641
    Mitobronitol

    Myelobromol; DBM

    		 DNA Alkylator/Crosslinker Cancer
    Mitobronitol (Myelobromol; DBM) is a brominated analog of mannitol, also known as an anticancer agent that is classified as an alkylating agent. Mitobronitol has potential for myelosuppression associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia .
    Mitobronitol
  • HY-19915B
    Contezolid acefosamil sodium

    MRX-4 sodium

    		 Bacterial Antibiotic Monoamine Oxidase Infection Inflammation/Immunology
    Contezolid acefosamil sodium (MRX-4), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid acefosamil sodium (MRX-4) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI) .
    Contezolid acefosamil sodium
  • HY-N7114
    Chloramphenicol succinate

    		Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase Infection Inflammation/Immunology
    Chloramphenicol succinate is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate exerts a significant inhibitory effect on colitis. Chloramphenicol succinate can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate
  • HY-179382
    HSB401

    		FLT3 Apoptosis Cancer
    HSB401 is an orally active FLT3 inhibitor (IC50: 28, 5, 72, 51 nM for FLT3-WT, FLT3-D835Y, FLT3-ITD-F691L, FLT3-ITD, respectively). HSB401 downregulates FLT3 signaling and induces cell cycle arrest and apoptosis. HSB401 spares c-KIT inhibition, thereby reducing the risk of myelosuppression. HSB401 significantly suppresses tumor growth in the MV4-11 xenograft mouse model. HSB401 can be used for the research of acute myeloid leukemia .
    HSB401
  • HY-111984A
    Quinazosin dihydrochloride

    		Adrenergic Receptor Cardiovascular Disease
    Quinazosin dihydrochloride is an antihypertensive α1-adrenergic receptor antagonist whose activity is associated with inhibition of granulopoiesis, resulting in neutropenia and leukopenia. Quinazosin dihydrochloride exhibits dose-related myelosuppression that is correlated with the duration of suppression .
    Quinazosin dihydrochloride
  • HY-W097899R
    Vanillylamine (Standard)

    		Reference Standards JNK Cancer
    Vanillylamine is an immediate precursor for capsaicinoids. Vanillylamine is a derivative of Vanillin (HY-N0098) is synthesized through a transaminase reaction in the phenylpropanoid pathway of capsaicinoid synthesis. Vanillylamine significantly alleviates myelosuppression caused by abdominal and pelvic tumor chemotherapy .
    Vanillylamine (Standard)
  • HY-N7114AR
    Chloramphenicol succinate sodium (Standard)

    		Reference Standards Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase Infection Inflammation/Immunology
    Chloramphenicol succinate sodium (Standard) is the analytical standard of Chloramphenicol succinate sodium. This product is intended for research and analytical applications. Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate sodium (Standard)
  • HY-10966R
    SB-590885 (Standard)
    Maximum Cited Publications
    8 Publications Verification

    		 Reference Standards Raf Apoptosis Cancer
    SB-590885 (Standard) is the analytical standard of SB-590885 (HY-10966). This product is intended for research and analytical applications. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
    SB-590885 (Standard)
  • HY-117947
    (R)-OR-S1

    		Histone Methyltransferase Cancer
    (R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.
    (R)-OR-S1
  • HY-106329
    DMDC

    		Others Cancer
    DMDC is an anti-tumor agent. DMDC induces chemotherapy-induced myelosuppression, characterized by decreases in leukocyte and neutrophil counts. DMDC can be used for the study of advanced malignancies .
    DMDC
  • HY-119200
    LY-195448 hydrochloride

    		Endogenous Metabolite Cancer
    LY-195448 hydrochloride is a phenethanolamine that exhibits anti-tumour activity across various murine tumour models. LY-195448 hydrochloride acts by blocking cells at metaphase. LY-195448 hydrochloride has demonstrated a lack of "standard" side effects commonly associated with cancer treatments, such as myelosuppression and gastrointestinal toxicity. LY-195448 hydrochloride was evaluated in a phase I trial, where it showed only mild and reversible side effects like hypotension, tachycardia, and tremor.
    LY-195448 hydrochloride
  • HY-101467R
    Trilaciclib (Standard)

    G1T28 (Standard)

    		 CDK Reference Standards Cancer
    Trilaciclib (Standard) is the analytical standard of Trilaciclib (HY-101467). This product is intended for research and analytical applications. Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
    Trilaciclib (Standard)
  • HY-10966G
    SB-590885

    		Raf Apoptosis Cardiovascular Disease Cancer
    SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
    SB-590885

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: